Valuation: Innoviva, Inc.

Capitalization 1.8B 1.52B 1.4B 1.32B 2.45B 166B 2.5B 16.39B 6.42B 80.51B 6.73B 6.59B 284B P/E ratio 2026 *
11.9x
P/E ratio 2027 * 10.9x
Enterprise value 1.29B 1.09B 1.01B 953M 1.77B 120B 1.8B 11.79B 4.62B 57.93B 4.84B 4.74B 204B EV / Sales 2026 *
2.94x
EV / Sales 2027 * 2.18x
Free-Float
98.93%
Yield 2026 *
-
Yield 2027 * -
1 day+2.71%
1 week+2.02%
Current month+4.03%
1 month+9.88%
3 months+24.69%
6 months+40.36%
Current year+21.26%
1 week 23.28
Extreme 23.275
24.44
1 month 21.62
Extreme 21.615
24.44
Current year 19
Extreme 19
25.14
1 year 16.52
Extreme 16.52
25.14
3 years 11.32
Extreme 11.32
25.14
5 years 10.64
Extreme 10.64
25.14
10 years 7.58
Extreme 7.58
25.14
Manager TitleAgeSince
Chief Executive Officer 42 2020-05-19
Director of Finance/CFO 60 2023-08-20
Investor Relations Contact - 2025-08-31
Director TitleAgeSince
Director/Board Member 75 2018-02-11
Director/Board Member 66 2018-02-11
Chairman 55 2023-05-21
Change 5d. change 1-year change 3-years change Capi.($)
+2.71%+2.02%+32.68%+101.66% 1.8B
+2.55%-1.32%+10.37%+148.97% 830B
-0.15%-1.79%+48.71%+41.35% 564B
-0.29%+0.21%+20.46%+29.28% 369B
+2.07%+1.39%+25.20%+15.13% 328B
+1.72%-0.74%+49.33%+27.86% 318B
+1.19%-2.41%+31.10%+34.87% 291B
+3.13%-1.94%+52.65%+3.53% 294B
+1.69%+1.22%+28.13%+43.23% 192B
+1.24%+8.21%-38.18%-55.23% 182B
Average +1.59%-0.12%+26.04%+39.06% 336.93B
Weighted average by Cap. +1.48%-0.62%+26.89%+53.75%

Financials

2026 *2027 *
Net sales 439M 372M 342M 324M 601M 40.66B 611M 4.01B 1.57B 19.71B 1.65B 1.61B 69.46B 495M 419M 386M 365M 677M 45.8B 689M 4.52B 1.77B 22.2B 1.86B 1.82B 78.25B
Net income 157M 133M 122M 116M 215M 14.52B 218M 1.43B 562M 7.04B 589M 577M 24.81B 185M 157M 144M 136M 253M 17.12B 257M 1.69B 662M 8.3B 694M 679M 29.25B
Net Debt -503M -426M -392M -371M -688M -46.59B -700M -4.6B -1.8B -22.58B -1.89B -1.85B -79.59B -717M -607M -559M -529M -980M -66.32B -997M -6.54B -2.57B -32.15B -2.69B -2.63B -113B
Logo Innoviva, Inc.
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. The Company's products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), is approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in Phase III clinical trial.
Employees
159
Date Price Change Volume
26-04-17 24.24 $ +2.71% 684,011
26-04-16 23.60 $ -1.34% 768,306
26-04-15 23.92 $ -1.12% 515,379
26-04-14 24.19 $ +0.92% 582,933
26-04-13 23.97 $ +0.88% 548,620
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
24.24USD
Average target price
33.20USD
Spread / Average Target
+36.96%

Quarterly revenue - Rate of surprise